Physiologic and pathophysiologic roles of AKAP12

Hui Li
Central Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, P. R. China

Abstract
A kinase anchoring protein (AKAP) 12 is a scaffolding protein that improves the specificity and efficiency of spatiotemporal signal through assembling intracellular signal proteins into a specific complex. AKAP12 is a negative mitogenic regulator that plays an important role in controlling cytoskeletal architecture, maintaining endothelial integrity, regulating glial function and forming blood-brain barrier (BBB) and blood retinal barrier (BRB). Moreover, elevated or reduced AKAP12 contributes to a variety of diseases. Complex connections between AKAP12 and various diseases including chronic liver diseases (CLDs), inflammatory diseases and a series of cancers will be tried to delineate in this paper. We first describe the expression, distribution and physiological function of AKAP12. Then we summarize the current knowledge of different connections between AKAP12 expression and various diseases. Some research groups have found paradoxical roles of AKAP12 in different diseases and further confirmation is needed. This paper aims to assess the role of AKAP12 in physiology and diseases to help lay the foundation for the design of small molecules for specific AKAP12 to correct the pathological signal defects.

Keywords
AKAP12, physiological function, CLDs, inflammatory disease, cancer

Introduction
A-Kinase Anchoring Proteins (AKAPs), a family of scaffolding protein, regulate intracellular signal transduction through sequestering protein kinases, phosphatases, and signal termination molecules, with their target substrates.1–4 AKAP12, also known as Gravin in human or Src-suppressed C kinase substrate (SSeCKS) in rodents, was originally isolated from a patient with myasthenia gravis.5–7 AKAP12, a member of the AKAPs family, modulates cell cycle and cytoskeletal architecture
through binding the regulatory subunit of cAMP-dependent protein kinase (PRKA), protein kinase C (PKC), protein phosphatase 2B, and calmodulin via a C terminal amphipathic helix. Moreover, AKAP12 improves the specificity and efficiency of spatiotemporal signal through assembling intracellular signal proteins into a specific complex.

Expression, distribution and physiological function of AKAP12

Expression and distribution

AKAP12 has three isoforms, which are encoded by three independent mRNAs (α, β and γ) located at 6q24-q25. Among them, AKAP12/A is 305 kDa, AKAP12/B is 287 kDa, and AKAP12/C is 250 kDa respectively. Three isoforms have more than 95% amino acid sequence homology except N-terminal sequence. The N-terminal myristylation motif of AKAP12α is required for the targeted expression of the AKAP12α isoform into the endoplasmic reticulum.

Three isoforms are expressed differentially in different organs. AKAP12α is widely expressed except in liver, while the distribution of AKAP12β is similar to AKAP12α, but to a lesser extent. AKAP12γ is mainly expressed in testis. In addition, the expression of AKAP12 is mainly observed on fibroblasts, neurons, cells from the neural crest such as glia, adrenal chromaffin cells, whereas the expression on endothelial cells is only found on liver sinusoidal endothelial cells (LSECs) and endothelial of intestinal lacteals. The expression of AKAP12 in hepatic sinusoidal is related to long-term exposure to intestinal bacterial endotoxin and inflammatory mediators released by mucosal and hepatic immune system cells in response to endotoxin. The distribution of three isoforms of AKAP12 in organs and the expression of AKAP12 in different cells are summarized in Table 1.

AKAP12 expression can be induced by phorbol ester and lysphosphatidylcholine. The expression of AKAP12 increases transiently in early G1 phase under mitogenic stimuli and decreases in the late G1 phase. AKAP12 is hyperphosphorylated on serine residues in G1/S phase, but not in G2/M phase. The tyrosine phosphorylation of AKAP12 may be directly modulated by EGF/PDGF dependent and Src independent proliferation pathways. Moreover, the expression of AKAP12 is orchestrated by ARHGEF18/p114RhoGEF, a tight junction-associated RhoA activator. To ensure

| Isoforms    | Expression in organs                        | Expression on cells                                                                 | References |
|-------------|---------------------------------------------|-------------------------------------------------------------------------------------|------------|
| AKAP12α     | Expressed broadly except in liver           | neurons, cells from neural crest such as glia and adrenal chromaffin cells, fibroblasts, endothelial cells including LSECs and endothelial of intestinal lacteals | 17,18      |
| AKAP12β     | Similar to AKAP12α and to a less extent     |                                                                                     |            |
| AKAP12γ     | Mainly expressed in testis                  |                                                                                     |            |
normal primary cilia length and renal epithelial morphogenesis, the expression of AKAP12 is regulated by Notch signaling.\textsuperscript{27}

**Physiological function**

AKAP12 is a negative mitogenic regulator, which is located in the whole cytoplasm and enriches in podosomes and cell margins, and it plays a part in controlling cytoskeletal architecture. AKAP12 shifts from the plasma membrane to the periphery of nucleus coincident with a loss of actin stress fibers, when administrated with phorbol ester for a short time.\textsuperscript{5,25,28} Instead of directly inhibiting src activity, AKAP12 quarantines the active enzyme from its downstream effectors.\textsuperscript{29} AKAP12 mainly causes the initial dissolution of actin, followed by the reappearance of stress fiber, so it does not inhibit the formation of actin-based structure. The serine phosphorylation of AKAP12 regulated by PKC and other kinases changes its interaction with the cytoskeleton matrix and its ability to control mitosis. Cell flattening induced by AKAP12 over-expression is associated with early G1 phase growth arrest of untransformed cells.\textsuperscript{20} Therefore, by reestablishing the actin cytoskeleton, AKAP12 is ready for subsequent cell division.\textsuperscript{30,31}

AKAP12 plays a pivotal role in the maintenance of endothelial integrity during vascular development through regulating the expression of p21-activated protein kinase (PAK2), an actin cytoskeletal regulator, and Afadin (AF6), a connector of intercellular adhesion molecules and the actin cytoskeleton. Without AKAP12, zebrafish embryos would display severe hemorrhages partly due to disorganized interendothelial cell-cell adhesions.\textsuperscript{32}

Moreover, AKAP12 is a key factor in regulating glial function. In mice, the expression level of AKAP12 in the corpus callosum is higher than in the cortex and decreases gradually with age. It is worth noting that AKAP12 is mainly expressed on postnatal astrocytes, not on oligodendrocyte precursor cells (OPC), another major type of glia in the developing corpus callosum. Compared to wild-type mice, AKAP12 knockout mice have fewer astrocytes and OPC, and the development of corpus callosum slows down after birth.\textsuperscript{33} AKAP12 regulates two processes of the blood-brain barrier (BBB) formation, including angiogenesis and tight junction formation. AKAP12 decreases the expression of vascular endothelial growth factor (VEGF) through activating protein-1 (AP-1) reduction and increases angiopeptin-1 (Ang-1) expression, an antipermeability factor in astrocytes.\textsuperscript{34} AKAP12 also induces the formation of blood retinal barrier (BRB) by enhancing Ang-1 in astrocytes and reducing the level of VEGF.\textsuperscript{35,36} The physiologic role of AKAP12 is summarized in Table 2.

**Role of AKAP12 in chronic liver diseases (CLDs)**

**Role of AKAP12 in hepatic fibrosis**

Recent research has increasingly focused on the relationship between AKAP12 and hepatic fibrosis. AKAP12 participates in a variety of factors including activation of hepatic stellate cells (HSCs), capillarization of LSECs, endothelial injury and hypoxia to promote fibrosis progression.
| Conditions       | Role of AKAP12                                                                 | References       |
|-----------------|-------------------------------------------------------------------------------|-----------------|
| **Physiology**  | Negative mitogenic regulator                                                  | 5,20,23,28,29,32–34 |
|                 | Controlling cytoskeletal architecture                                          |                 |
|                 | Quarantines the active enzyme from its downstream effectors                   |                 |
|                 | Inducing cell flattening over-expression                                       |                 |
|                 | Maintaining endothelial integrity                                             |                 |
|                 | Regulating glial function                                                     |                 |
|                 | Decreasing VEGF and AP-1, Increasing Ang-1                                    | 37–55           |
| **CLDs**        | Activating HSCs in hepatic fibrosis induced by CCl4                            |                 |
|                 | Be involved in the process of actin skeleton remodeling                        |                 |
|                 | Up-regulating Col α1, elastin and EpCAM                                       |                 |
|                 | Reducing angiogenesis, ET-1                                                    |                 |
|                 | Inhibiting ECM accumulation and vascular remodeling                           |                 |
| **Hepatic fibrosis** | Hindering PFs activation                                                       |                 |
|                 | Promoting fibrosis resolution                                                  |                 |
|                 | Improving vascular endothelial dysfunction                                     |                 |
|                 | Reducing ROS                                                                   |                 |
|                 | Increasing eNOS                                                                 |                 |
| **NAFLD**       | Promoting plaque formation in the aorta.                                      | 56,57           |
|                 | Enhancing lipid accumulation and damage in the liver                           |                 |
|                 | Promoting hyperlipidemia and atherosclerosis                                   |                 |
| **ALD**         | Inhibiting the activation of HSCs                                              | 58              |
| **Inflammatory Diseases** | Hindering liver fibrosis through impeding HSP47-collagen interaction | 59–61           |
|                 | Decreasing in Ang II-induced cardiac injury                                    |                 |
|                 | Attenuating oxidative stress, inflammation, apoptosis, autophagy and severe tissue damage |                 |
|                 | Alleviating myocardial fibrosis through inhibiting TGF-β1 pathway              |                 |
|                 | Improving cardiac histologic alterations, and cardiac dysfunction and heart failure |                 |
|                 | Be related to the presence of extensive colitis                               |                 |

(Continued)
| Conditions                  | Role of AKAP12                                                                 | References |
|----------------------------|-------------------------------------------------------------------------------|------------|
| Various Cancers            |                                                                               | 62–65      |
| Lung Tumor                 | Inhibiting growth and metastasis of tumor                                      | 66–69      |
|                            | Impairing the activity of telomerase                                           |            |
| Meningioma                 | Inhibiting proliferation, migration, invasion                                  | 70–72      |
| Colorectal Carcinoma       | Reducing tumor volume                                                          | 73–76      |
|                            | Promoting apoptosis                                                            |            |
|                            | Suppressing tumor growth                                                       |            |
| Breast Cancer              | SUPPENDING cell migration                                                      | 77,78      |
|                            | Increasing relapse-free survival                                               |            |
| Gastric Cancer             | Supressing the invasion and metastasis                                         | 79         |
| Prostate Cancer            | Suppressing invasion, metastasis and cancer recurrence                        | 80–84      |
|                            | Be related to DTX-resistance                                                   |            |
| Myeloid malignancies       | Prolonging cell cycle                                                          | 85,86      |
|                            | Inhibiting cell proliferation                                                  |            |
|                            | Inducing apoptosis                                                             |            |
| Reproductive system tumor  | Inhibiting cell division of seminiferous tubules in the testis                 | 87,88      |
| Other Cancers              | Be a poor prognosis and predictor of PFS and OS in serous ovarian cancer       | 89–91      |
|                            | Inhibiting Lung Metastasis And Colonization Of Metastatic Melanoma             |            |
|                            | Inhibiting Tumor Viability In Fibrosarcoma HT1080 Cells                       |            |
AKAP12 helps activate HSCs, which can regulate the formation of liver regeneration or liver fibrosis after various injuries.\textsuperscript{37} The expression of AKAP12 rises in both liver tissues of acute liver failure and activated HSCs induced by CCl4, and may also be involved in the process of actin skeleton remodeling in HSCs.\textsuperscript{37,38} Platelet-derived growth factor (PDGF), a growth factor promoting HSCs proliferation and playing an important role in progression of liver fibrosis,\textsuperscript{39–41} is able to induce AKAP12 tyrosine phosphorylation and rapid rearrangement of the cytoskeletal network in rat HSCs, which is mediated by PKC through Rho protein.\textsuperscript{42}

Similarly, the expression of AKAP12 on LSECs increases significantly after the hepatic injury stimulated by lipopolysaccharide (LPS).\textsuperscript{43} However, after 8 weeks of thioacetamide (TAA) administration, the expression of AKAP12 drops in capillary endothelium. AKAP12 reduces the expression of collagen type 1 α1, elastin and encoding epithelial cell adhesion molecule (EpCAM), but no significant change in extracellular matrix (ECM) accumulation is observed.\textsuperscript{44} And with liver fibrosis progression, AKAP12 expression on portal fibroblasts (PFs) and LSECs diminishes gradually. AKAP12 reduces angiogenesis and endothelin-1 (ET-1) expression, inhibits ECM accumulation and vascular remodeling, hinders the activation of PFs, promotes fibrosis resolution and normalizes myofibroblasts and capillarized sinusoids in a DDC-induced biliary fibrosis model.\textsuperscript{45} The aforementioned paradox results reflect the complexity of AKAP12 regulation in the development of liver fibrosis.

In addition, AKAP12 is correlated with vascular integrity which plays an important role in the development of liver fibrosis.\textsuperscript{34,46} AKAP12 is conducive to endothelial barrier function and is essential for cAMP-mediated barrier stabilization.\textsuperscript{8,47,48} AKAP12 also improves vascular endothelial dysfunction induced by LPS, reduces the level of reactive oxygen species (ROS) and pro-inflammatory factors, increases endothelial nitric oxide synthase (eNOS), and promotes transcriptional activity of extracellular-signal-regulated kinase 5 (ERK5) through inhibiting PKCζ.\textsuperscript{49} AKAP12 may play a role in endothelial injury healing by targeting PKA and PKC to specific membrane associated sites.\textsuperscript{21} Past results suggest that PKC promotes hepatic fibrogenesis and its inhibitor can hinder liver fibrosis. The level of oxidized diacylglycerol (DAG), which is a type of activator of PKC, elevates in the mouse model induced by CCl4.\textsuperscript{50–52} The expression of AKAP12 is higher on VEGF stimulated endothelial cells with active migration, but lower in quiescent endothelial cells.\textsuperscript{53,54}

Hypoxia, another important factor related to the development of liver fibrosis, can induce the expression of AKAP12. There are 2 binding sites for hypoxia-inducible factor (HIF) in AKAP12 and the most distal HIF-binding site is key to hypoxia-induced AKAP12 expression. AKAP12 inhibits angiogenesis, enhances junctional permeability in a hypoxia-inducible factor-1α (HIF-1α)-dependent manner and acts as a “brake” system for angiogenesis. Furthermore, AKAP12 controls the response of endothelial barrier function to PKA agonists.\textsuperscript{55} The roles of AKAP12 in hepatic fibrosis are summarized in Table 2.

\textbf{Role of AKAP12 in NAFLD}

AKAP12 is involved in the development and progression of non-alcoholic steatohepatitis (NASH) and may represent potential targets of therapy for NASH-related
inflammation.\textsuperscript{56} Fan and McConnell’s team recently reported that the role of AKAP12 in a mouse model with atherosclerosis induced by HFD. AKAP12-mediated signaling complex increases plaque formation in the aorta, enhances lipid accumulation and damage in the liver of HFD mice and promotes hyperlipidemia and atherosclerosis by inhibiting the expression of sterol regulatory element-binding protein-2 (SREBP-2) and liver 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA).\textsuperscript{57} The roles of AKAP12 in NAFLD are well documented in Table 2.

**Role of AKAP12 in ALD**

Liver injury induced by alcohol exposure increases the phosphorylation of AKAP12. Evidentially, elevated phosphorylation of AKAP12 is found in ALD/alcoholic hepatitis patients. AKAP12 inhibits the activation of HSCs and the interaction between AKAP12 and heat shock protein 47 (HSP47) hinders liver fibrosis through impeding HSP47-collagen interaction. Augmented phosphorylation of AKAP12 induced by ethanol can down-regulate the scaffolding activity of AKAP12 for PKC/cyclin-D1 in HSCs but not in hepatocytes. Ethanol promotes the activation of HSCs by increasing the phosphorylation of AKAP12 and up-regulating the interaction between HSP47 and collagen.\textsuperscript{58} Table 2 demonstrates the roles of AKAP12 in ALD.

**Role of AKAP12 in inflammatory diseases**

Dysregulated angiotensin II (Ang II) is a key effector of hypertension and cardiac fibrosis that could lead to a series of inflammatory responses. The expression of AKAP12 decreases in Ang II-induced cardiac injuries and the number of inflammatory cells increases in AKAP12 knock-out mice. Moreover, AKAP12 attenuates oxidative stress, inflammation, apoptosis, autophagy and alleviates myocardial fibrosis by inhibiting the TGF-β1 pathway. AKAP12 depletion worsens cardiac histologic alterations and then leads to cardiac dysfunction and heart failure.\textsuperscript{59} However, heat shock protein A12B (HSPA12B) over-expression shows cardioprotection along with reduced fibrosis, and increased capillary and arteriolar density in a rat model of diabetic myocardial infarction through down-regulating the expression of AKAP12 and up-regulating VEGF and thioredoxin 1 (Trx1) expression.\textsuperscript{92,93}

Similarly, increased AKAP12-positive cells in the new tissue formation stage attenuate excessive inflammation and severe tissue damage, and express junction proteins to form a physical barrier after central nervous system (CNS) injury.\textsuperscript{60}

However, the over-expression of AKAP12 in patients with ulcerative colitis (UC) is related to the presence of extensive colitis. The expression of AKAP12 in the colonic mucosa of patients with active UC up-regulates, while that in patients with UC remission down-regulates.\textsuperscript{61} In addition, elevated AKAP12 level induced by IL-1β and TNF-α in rat pulmonary microvascular endothelial cells is correlated with the endothelial hyperpermeability in the inflammatory process and aggravates endothelial barrier dysfunction.\textsuperscript{94} The roles of AKAP12 in inflammatory diseases are illustrated in Table 2.
Role of AKAP12 in various cancers

AKAP12 functions as a tumor suppressor in a variety of cancers that can block the cell cycle and inhibit angiogenesis proliferation, chemotaxis and invasion of cancer cells by hindering PKC activation. The expression of AKAP12 declines in various human cancers, including hepatocellular carcinoma (HCC), breast cancer, gastric cancer, prostate cancer, myelodysplastic syndromes (MDS), colon cancer, skin cancer, and seminoma, etc.

Over-expression or deficiency of AKAP12 in cells changes susceptibility to the progression of malignancy or metastasis and AKAP12-deficient mice also show higher tumor incidence. The anti-proliferative effect of colchicine on HCC cells partially correlates with the expression of AKAP12. MiR-103 or MiR-1251-5p promotes cell proliferation and inhibits apoptosis of HCC cells by suppressing the expression of AKAP12 and encouraging protein kinase Cα (PKCα) activities. In meningioma, levels of expression of AKAP12 and non-coding RNA maternally expressed gene3 (MEG3) decreases and miR-29c increases. Elevated levels of MEG3 and the absence of miR-29c can diminish cell cycle, migration, invasion, and proliferation in meningioma cells. The expression of AKAP12 is co-regulated by MEG3/miR-29c axis and AKAP12 depletion restores the above inhibitory effects induced by miR-29c absence in vitro. Down-regulated expression of AKAP12 in patients is related to tumor recurrence and progression and indicates poor prognosis. Low AKAP12 expression through AKAP12 knockdown in benign meningioma cells SF4433 can promote proliferation, migration, invasion, and proliferation in meningioma cells. The expression of AKAP12 is down-regulated and is related to the overall survival (OS) of patients with breast carcinoma. Patients with AKAP12 expression have higher relapse-free survival. AKAP12 knockdown induces cell migration but does not alter cell proliferation, thus AKAP12 acts as a potential metastasis suppressor in breast cancer. AKAP12A may function as an important negative regulator of the survival pathway in human gastric cancer. AKAP12 is weakly expressed in gastric cancer and can suppress the invasion and metastasis in gastric cancer cells. The expression of AKAP12 significantly diminishes in myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myeloid leukemia (CML). MiR-144 reduces AKAP12 expression through binding to AKAP12 3’UTR in hematopoietic cells. Compared to normal skin tissue, AKAP12 is significantly down-regulated in cutaneous squamous cell carcinomas (cSCCs). AKAP12 expression in retinoblastoma patient tissue reduces significantly, while the expression of VEGF increases. The content of AKAP12 in human seminoma cells is lower than that in normal cells. In mice lacking AKAP12, cells in the area called seminiferous tubules in the testis divide faster, which is a hallmark of cancer. The loss of AKAP12 is accompanied by the reduction of two important cell cycle regulatory kinases Aurora A and Plk. In addition, both over-expression of AKAP12 and down-regulation of PKCα can inhibit the growth and metastasis of the tumor by impairing the activity of telomerase.

Promoter hypermethylation rises as the basis for the loss of AKAP12 expression in a variety of cancers and is an underlying biomarker for cancer progression and metastasis. AKAP12 is down-regulated by promoter hypermethylation or 6q24-25.2 deletion in HCC tissues and hypermethylation of the promoter of the AKAP12 gene has been
observed in 85% of HCC tissues.62–64 AKAP12 DNA methylation is closely related to the low risk of recurrence and long-progression-free survival of patients with HCC.65 The high percentage of methylated AKAP12 in patients with advanced colorectal cancer indicates that AKAP12 methylation can be used as a marker to monitor the progression of colorectal cancer.74–76 The 5′ CpG islands of both AKAP12A and AKAP12B are often hypermethylated in gastric cancer cells. DNA methylation can inhibit the expression of AKAP12 in gastric cancer cells through transcriptional silencing. Suppressing DNA methylation leads to the restoration of AKAP12 expression, followed by reducing the formation of the colon and promoting apoptotic cell death.103 AKAP12 is expressed and characterized by an unmethylated 5′ CpG island in normal hematopoietic progenitors but is transcriptionally silent and characterized by hypermethylation in leukemic blasts. Moreover, AKAP12 hypermethylation is also observed in refractory anemia with excess blasts (RAEB) and acute myeloid leukemia (AML).86 AKAP12 methylation is significantly higher in Barrett’s esophagus patients than in controls.104 Hypermethylation frequency is zero in normal esophagus but is elevated early during neoplastic progression, to 38.9%, 52.5% and 52.2% in the patients with Barrett’s alone, dysplastic Barrett’s metaplasia, and esophageal adenocarcinoma (EAC) respectively.105

In addition, AKAP12 can suppress tumor growth by regulating cytokinesis progression. AKAP12 localizes to the cell periphery during interphase, and localizes to the actomyosin contractile ring during cytokinesis. The inhibition of myosin light chain kinase (MLCK), a key regulator of actomyosin contractility, removes AKAP12 from the cell periphery during interphase and from the contractile ring during cytokinesis, suggesting that AKAP12 might be one of the downstream effectors of MLCK. AKAP12 depletion increases the number of multinucleated cells, and disrupts the completion of cytokinesis.106 Up-regulation of AKAP12 can prolong the cell cycle, inhibit cell proliferation, and induce apoptosis.96

AKAP12 can reduce tumor volume and promote apoptosis of colorectal cancer, which helps suppress tumor growth and improves the survival of human colorectal cancer.73,97,98 AKAP12 inhibits lung metastasis and colonization of metastatic melanoma by reducing the expression of selectin adhesion protein.89,90 AKAP12 impedes peritoneal metastasis induced by B16F10, a type of murine melanoma cell line, by reducing the secretion of CXCL9/10 by resident fibroblasts.16 In fibrosarcoma HT1080 cells, AKAP12 inhibits tumor viability by inducing apoptosis via caspase-3, which is related to the Bcl-2 expression down-regulation and Bax expression up-regulation.91 Moreover, phosphorylation can change the scaffold activity of AKAP12 and inhibit its binding with PKC, thus enhancing PKC activities.47 The association between the 6q25.1 locus and breast cancer risk may be mediated through single nucleotide polymorphisms (SNPs) that regulate the expression of the AKAP12 gene.107

AKAP12 regulates endothelial cell migration by inhibiting the expression of matrix metalloproteinase 9 (MMP-9) in tumor cells, which plays an important role in the degradation of ECM molecules followed by tumor metastasis and angiogenesis.108 Different roles of AKAP12 in regulating MMPs may be involved in the different substrates specificities between the endothelial cell and vascular smooth muscle cells (VSMCs).57,109 By reducing MMP-9 and HIF-1α, AKAP12 can regulate angiogenesis in NIH3T3 cell lines.110

It is noteworthy that the roles of AKAP12 in lung tumors, prostate cancer and ovarian cancer are controversial. Different research groups have made opposite conclusions on the
role of AKAP12 played in lung cancer.\textsuperscript{66–69,111} Ma et al. observed down-regulation of AKAP12, up-regulation of VEGF and angiopoietin-1 in mice with lung tumors.\textsuperscript{66} AKAP12\(\alpha\) expression is regulated by DNA methylation and reduced expression is observed in lung cancer cells. Compared to normal tissues, the AKAP12\(\alpha\) promoter is more frequently methylated in tumors and AKAP12\(\alpha\) promoter methylation is associated with lung cancer prognosis.\textsuperscript{67,68} Transcription factor activated enhancer-binding protein 2C (TFAP2C) can promote lung tumorigenesis and aggressiveness by inducing the overexpression of oncogenic microRNA (miRNA)-183 and then blocking AKAP12-mediated cyclin inhibition.\textsuperscript{69} Contrary to the above-mentioned results, Chang et al. group demonstrated that AKAP12 was a tumor promoter in the development of lung adenocarcinoma. Elevated miR-338-3p inhibited the expression level of AKAP12 in lung cancer cells and helped improve the prognosis.\textsuperscript{111}

The expression of AKAP12 reduces in human prostate cancer cell lines including PC-3, PPC-1, LNCaP, DU145, and TSU and rat prostate cancer cell lines such as AT3.1 and MatLyLu. Loss of AKAP12 is related to the increased metastatic progression of human prostate cancer.\textsuperscript{80} AKAP12 has been reported to suppress invasion, metastasis and cancer recurrence by inducing heterotypic repulsion between human prostate cancer and microvessel endothelial cells, inhibiting VEGF expression and enhancing soluble anti-angiogenic factors.\textsuperscript{81,82} The combined loss of AKAP12 and Rb in the prostate leads to early metastasis to the lymph node in prostate cancer.\textsuperscript{83} By inducing AKAP12 promoter demethylation and then increasing the expression of AKAP12, peroxisome proliferator-activated receptor gamma 2 (PPARG2) inhibits cell migration, colony formation, and invasion of prostate cancer cells in vitro.\textsuperscript{84} However, there is another result indicating the roles of AKAP12 in promoting prostate cancer progression. The expression of the long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) enhances in docetaxel (DTX)-resistant prostate cancer cells. MiR-145-5p is a target of MALAT1, and AKAP12 is a target of miR-145-5p. Over-expression of MALAT1 promotes proliferation, migration, and invasion of prostate cancer cells and inhibits expression of miR-145-5p in prostate cancer cells, then enhances their chemo-resistance to DTX. Over-expression of AKAP12, is related to chemo-resistance to DTX in prostate cancer cells, can be suppressed by miR-145-5p.\textsuperscript{112} Interestingly, AKAP12 is highly expressed in paclitaxel resistant advanced serous ovarian cancer cells and is a poor prognosis and predictor of progression-free survival (PFS) and OS in serous ovarian cancer patients.\textsuperscript{88}

The roles of AKAP12 in various cancers including HCC, lung tumor, meningioma, colorectal carcinoma, breast cancer, gastric cancer, prostate cancer, myeloid malignancies, reproductive system tumor, etc. are summarized in Table 2.

**Conclusion and future perspectives**

AKAP12 is a negative mitogenic regulator and is crucial in controlling cytoskeletal architecture, maintaining endothelial integrity, regulating glial function and forming the BBB and BRB. AKAP12, a scaffolding protein, can improve the specificity and efficiency of spatiotemporal signals by assembling intracellular signal proteins into a specific complex.

AKAP12 has exhibited paradoxical results and complex relationships with a variety of diseases including CLDs, inflammatory diseases and various cancers. AKAP12 expression
increases in activated HSCs stimulated by CCl4 and in LSECs stimulated by LPS; paradoxically, the expression of AKAP12 decreases in capillarized endothelium in liver fibrosis induced by TAA and DDC. AKAP12 is related to normalizes myofibroblasts, capillarized sinusoids and fibrosis resolution. In addition, AKAP12 inhibits angiogenesis, enhances junctional permeability in a HIF-1α-dependent manner and acts as a “brake” system for angiogenesis. Therefore, further research is necessary to investigate the role of AKAP12 in the development and progression of liver fibrosis, especially within patients with liver fibrosis. AKAP12 is also involved in the development and progression of NASH and may represent potential targets of therapy for NASH-related inflammation. Ethanol promotes the activation of HSCs by increasing the phosphorylation of AKAP12 and up-regulating the interaction between HSP47 and collagen in ALD. In a word, the role of AKAP12 in CLDs is not consistent and needs to be addressed further.

In inflammatory diseases, AKAP12 attenuates oxidative stress, inflammation, apoptosis, autophagy and alleviates myocardial fibrosis, however, HSPA12B plays a cardioprotective role by reducing AKAP12 levels and the over-expression of AKAP12 in patients with UC is related to the presence of extensive colitis. Further elucidation is needed to understand the inconsistencies.

As a tumor suppressor, AKAP12 expression decreases in patients with HCC, meningioma, colorectal carcinoma, breast cancer, gastric cancer, myeloid malignancies, seminoma, and etc. Promoter hypermethylation is the most important reason for the lower expression of AAKP12. However, AKAP12 has exhibited mixed effects on lung cancer, prostate cancer and ovarian cancer, which deserves further investigation.

Ultimately, the role of AKAP12 in various diseases has generated wide interest that could lead to the design of small molecules for specific AKAP12 to correct the pathological signal defects in a variety of diseases.

Acknowledgements

This work was supported by Sichuan Science and Technology Program (No. 2020YFS0379).

Thank Miao Long for proofreading this manuscript.

Conflicts of interest

Hui Li declare that there is no competing interest.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Sichuan Science and Technology Program, (grant number 2020YFS0379).

ORCID iD

Hui Li https://orcid.org/0000-0002-5919-1396

References

1. Qasim H and McConnell BK. AKAP12 Signaling Complex: impacts of compartmentalizing cAMP-dependent signaling pathways in the heart and Various signaling systems. J Am Heart Assoc 2020; 9: e016615.
2. Diviani D and Scott JD. AKAP Signaling complexes at the cytoskeleton. *J Cell Sci* 2001; 114: 1431–1437.
3. Dell’Acqua ML and Scott JD. Protein kinase A anchoring. *J Biol Chem* 1997; 272: 12881–12884.
4. Feliciello A, Gottesman ME and Avvedimento EV. The biological functions of A-kinase anchor proteins. *J Mol Biol* 2001; 308: 99–114.
5. Nauert JB, Klauck TM, Langeberg LK, et al. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. *Curr Biol* 1997; 7: 52–62.
6. Gordon T, Grove B, Loftus JC, et al. Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera. *J Clin Invest* 1992; 90: 992–999.
7. Wu X, Wu T, Li K, et al. The mechanism and influence of AKAP12 in different cancers. *Biomed Environ Sci* 2018; 31: 927–932.
8. Gelman IH. Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12. *Cancer Metastasis Rev* 2012; 31: 493–500.
9. Chapline C, Moussseau B, Ramsay K, et al. Identification of a major protein kinase C-binding protein and substrate in rat embryo fibroblasts. Decreased expression in transformed cells. *J Biol Chem* 1996; 271: 6417–6422.
10. Lin X and Gelman IH. Calmodulin and cyclin D anchoring sites on the Src-suppressed C kinase substrate, SSeCKS. *Biochem Biophys Res Commun* 2002; 290: 1368–1375.
11. Shih M, Lin F, Scott JD, et al. Dynamic complexes of beta2-adrenergic receptors with protein kinases and phosphatases and the role of gravin. *J Biol Chem* 1999; 274: 1588–1595.
12. Coats SR, Covington JW, Su M, et al. SSeCKS gene expression in vascular smooth muscle cells: regulation by angiotensin II and a potential role in the regulation of PAI-1 gene expression. *J Mol Cell Cardiol* 2000; 32: 2207–2219.
13. Wong W and Scott JD. AKAP Signalling complexes: focal points in space and time. *Nat Rev Mol Cell Biol* 2004; 5: 959–970.
14. Diviani D, Marie D, Pérez López I, et al. A-kinase anchoring proteins: molecular regulators of the cardiac stress response. *Biochim Biophys Acta* 2013; 1833: 901–908.
15. Han B, Poppinga WI and Schmidt M. Scaffolding during the cell cycle by A-kinase anchoring proteins. *Pflugers Arch* 2015; 467: 2401–2411.
16. Muramatsu M, Gao L, Peresie J, et al. SSeCKS/AKAP12 scaffolding functions suppress B16F10-induced peritoneal metastasis by attenuating CXCL9/10 secretion by resident fibroblasts. *Oncotarget* 2017; 8: 70281–70298.
17. Streb JW, Kitchen CM, Gelman IH, et al. Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. *J Biol Chem* 2004; 279: 56014–56023.
18. Grove BD and Bruchey AK. Intracellular distribution of gravin, a PKA and PKC binding protein, in vascular endothelial cells. *J Vasc Res* 2001; 38: 163–175.
19. Gerthoffer WT. Actin cytoskeletal dynamics in smooth muscle contraction. *Can J Physiol Pharmacol* 2005; 83: 851–856.
20. Lin X, Nelson P and Gelman IH. SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D. *Mol Cell Biol* 2000; 20: 7259–7272.
21. Xia W and Gelman IH. Mitogen-induced, FAK-dependent tyrosine phosphorylation of the SSeCKS scaffolding protein. *Exp Cell Res* 2002; 277: 139–151.
22. Yamamoto M, Tamakawa S, Yoshiie M, et al. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. *Mol Carcinog* 2006; 45: 901–913.
23. Gelman IH, Lee K, Tombre E, et al. Control of cytoskeletal architecture by the src-suppressed C kinase substrate, SSeCKS. *Cell Motil Cytoskeleton* 1998; 41: 1–17.

24. Beal R, Alonso-Carriazo Fernandez A, Grammatopoulos DK, et al. ARHGEF18/p114RhoGEF Coordinates PKA/CREB signaling and actomyosin remodeling to promote trophoblast cell-cell fusion during placenta morphogenesis. *Front Cell Dev Biol* 2021; 9: 658006.

25. Mukherjee M, Ratnayake I, Janga M, et al. Notch signaling regulates Akap12 expression and primary cilia length during renal tubule morphogenesis. *FASEB J* 2020; 34: 9512–9530.

26. Sato N, Kokame K, Shimokado K, et al. Changes of gene expression by lysophosphatidylcholine in vascular endothelial cells: 12 up-regulated distinct genes including 5 cell growth-related, 3 thrombosis-related, and 4 others. *J Biochem* 1998; 123: 1119–1126.

27. Grove BD, Bowditch R, Gordon T, et al. Restricted endothelial cell expression of gravin in vivo. *Anat Rec.* 1994; 239: 231–242.

28. Lin X, Tombre E, Nelson PJ, et al. A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. *J Biol Chem* 1996; 271: 28430–28438.

29. Esseltine JL and Scott JD. AKAP Signaling complexes: pointing towards the next generation of therapeutic targets? *Trends Pharmacol Sci* 2013; 34: 648–655.

30. Nelson PJ and Gelman IH. Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: correlation with culture confluency, cell cycle phase and serum response. *Mol Cell Biochem* 1997; 175: 233–241.

31. Lin X and Gelman IH. Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. *Cancer Res* 1997; 57: 2304–2312.

32. Kwon HB, Choi YK, Lim JJ, et al. AKAP12 Regulates vascular integrity in zebrafish. *Exp Mol Med* 2012; 44: 225–235.

33. Takase H, Hamanaka G, Ohmoto R, et al. Roles of A-kinase anchor protein 12 in astrocyte and oligodendrocyte precursor cell in postnatal corpus Callosum. *Stem Cell Rev Rep* 2021; 17: 1446–1455.

34. Lee SW, Kim WJ, Choi YK, et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. *Nat Med* 2003; 9: 900–906.

35. Choi YK, Kim JH, Kim WJ, et al. AKAP12 Regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha. *J Neurosci* 2007; 27: 4472–4481.

36. Choi YK and Kim KW. AKAP12 In astrocytes induces barrier functions in human endothelial cells through protein kinase Czeta. *FEBSJ* 2008; 275: 2338–2353.

37. You T, Fan Y, Li Q, et al. Increased SSeCKS expression in rat hepatic stellate cells upon activation in vitro and in vivo. *Inflammation* 2013; 36: 1415–1423.

38. Jiang W, Song L, Shao JG, et al. The role of hepatic stellate cells SSeCKS expression in liver fibrosis. *Zhonghua Nei Ke Za Zhi* 2008; 47: 570–573.

39. Jiang W, Shao JG, Liu HO, et al. Expressions of src-suppressed C kinase substrate in lipopolysaccharide injured rat livers. *Zhonghua Gan Zang Bing Za Zhi* 2008; 16: 57–58.

40. Lee HS, Choi J, Son T, et al. A-kinase anchoring protein 12 is downregulated in human hepatocellular carcinoma and its deficiency in mice aggravates thioacetamide-induced liver injury. *Oncol Lett* 2018; 16: 5907–5915.

41. Lee HS, Choi J, Son T, et al. Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolution. *Exp Mol Med* 2018; 50: 1–13.

42. Barnett ME, Madgwick DK and Takemoto DJ. Protein kinase C as a stress sensor. *Cell Signal* 2007; 19: 1820–1829.

43. Yang JI, Yoon JH, Bang YJ, et al. Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. *Am J Physiol Gastrointest Liver Physiol* 2010; 298: G126–G132.
44. Toriumi K, Horikoshi Y, Yoshiyuki Osamura R, et al. Carbon tetrachloride-induced hepatic injury through formation of oxidized diacylglycerol and activation of the PKC/NF-κB pathway. *Lab Invest* 2013; 93: 218–229.

45. Weissmüller T, Glover LE, Fennimore B, et al. HIF-dependent regulation of AKAP12 (gravin) in the control of human vascular endothelial function. *FASEB J* 2014; 28: 256–264.

46. Radeva MY, Kugelmann D, Spindler V, et al. PKA Compartmentalization via AKAP220 and AKAP12 contributes to endothelial barrier regulation. *PLoS One* 2014; 9: e106733.

47. Gelman IH. Emerging roles for SSeCKS/gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis. *Genes Cancer* 2010; 1: 1147–1156.

48. Lee HS, Han J, Bai HJ, et al. Brain angiogenesis in developmental and pathological processes: regulation, molecular and cellular communication at the neurovascular interface. *FEBS J* 2009; 276: 4622–4635.

49. Li Z, Hu J, Guo J, et al. SSeCKS/Gravin/AKAP12 inhibits PKCzeta-mediated reduction of ERK5 transactivation to prevent endotoxin-induced vascular dysfunction. *Cardiovasc Toxicol* 2019; 19: 372–381.

50. Benz PM, Ding Y, Stingl H, et al. AKAP12 Deficiency impairs VEGF-induced endothelial cell migration and sprouting. *Acta Physiol (Oxf)* 2020; 228: e13325.

51. Walker-Gray R and Klussmann E. The role of AKAP12 in coordination of VEGF-induced endothelial cell motility. *Acta Physiol (Oxf)* 2020; 228: e13359.

52. Roehlen N, Crouch E and Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. *Cells* 2020; 9: 875.

53. Borkham-Kamphorst E and Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. *Cytokine Growth Factor Rev* 2016; 28: 53–61.

54. Ying HZ, Chen Q, Zhang WY, et al. PDGF Signaling pathway in hepatic fibrosis pathogenesis and therapeutic (review). *Mol Med Rep* 2017; 16: 7879–7889.

55. Di Sario A, Bendia E, Svegliati-Baroni G, et al. Rearrangement of the cytoskeletal network induced by platelet-derived growth factor in rat hepatic stellate cells: role of different intracellular signalling pathways. *J Hepatol* 2002; 36: 179–190.

56. Zhang L, Shao J, Xiao F, et al. Mechanism of expression of the Src family kinases (Fgr, Hck, Lyn) and SSeCKS in non-alcoholic steatohepatitis. *Zhonghua Gan Zang Bing Za Zhi*. 2015; 23: 363–367.

57. Fan Q, Yin X, Rababa’h A, et al. Absence of gravin-mediated signaling inhibits development of high-fat diet-induced hyperlipidemia and atherosclerosis. *Am J Physiol Heart Circ Physiol* 2019; 317: H793–H810.

58. Ramani K, Tomasi ML, Berlind J, et al. Role of A-kinase anchoring protein phosphorylation in alcohol-induced liver injury and hepatic stellate cell activation. *Am J Pathol* 2018; 188: 640–655.

59. Li Y, Yu QH, Chu Y, et al. Blockage of AKAP12 accelerates angiotensin II (ang II)-induced cardiac injury in mice by regulating the transforming growth factor beta1 (TGF-beta1) pathway. *Biochem Biophys Res Commun* 2018; 499: 128–135.

60. Cha JH, Wee HJ, Seo JH, et al. AKAP12 Mediates barrier functions of fibrotic scars during CNS repair. *PLoS One* 2014; 9: e94695.

61. Fonseca-Camarillo G, Furuzawa-Carballeda J, Priego-Ranero ÁA, et al. AKAP12/Gravin Is over-expressed in patients with ulcerative colitis. *Immunol Res* 2021; 69: 429–435.

62. Hayashi M, Nomoto S, Kanda M, et al. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. *J Surg Oncol* 2012; 105: 381–386.

63. Goeppe B, Schmezer P, Dutrue J, et al. Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. *Hepatology* 2010; 52: 2023–2033.
64. Han S, Wang L, Sun L, et al. MicroRNA-1251-5p promotes tumor growth and metastasis of hepatocellular carcinoma by targeting AKAP12. *Biomed Pharmacother* 2020; 122: 109754.

65. Liu ZJ, Liu W, Cui CH, et al. Association between A-kinase anchor proteins 12 methylation and recurrence of hepatocellular carcinoma. *Zhonghua Yu Fang Yi Xue Za Zhi* 2017; 51: 848–852.

66. Ma H, Lu T, Zhang X, et al. HSPA12B: a novel facilitator of lung tumor growth. *Oncotarget* 2015; 6: 9924–9936.

67. Jo UH, Whang YM, Sung JS, et al. Methylation of AKAP12 {alpha} promoter in lung cancer. *Anticancer Res* 2010; 30: 4595–4600.

68. Tessema M and Belinsky SA. Mining the epigenome for methylated genes in lung cancer. *Proc Am Thorac Soc* 2008; 5: 806–810.

69. Kang J, Kim W, Lee S, et al. TFAP2C Promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. *Oncogene* 2017; 36: 1585–1596.

70. Ding C, Yi X, Xu J, et al. Long non-coding RNA MEG3 modifies cell-cycle, migration, invasion, and proliferation through AKAP12 by sponging miR-29c in meningioma cells. *Front Oncol.* 2020; 10: 537763.

71. Parada CA, Osbun J, Kaur Jr., et al. Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. *Sci Rep* 2018; 8: 2098.

72. Sofela AA, McGavin L, Whitfield PC, et al. Biomarkers for differentiating grade II meningiomas from grade I: a systematic review. *Br J Neurosurg* 2021; 35: 696–702.

73. Li 15
84. Li F, Lu T, Liu D, et al. Upregulated PPARG2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer. *Cell Death Dis* 2021; 12: 528.
85. Boulwood J, Pellagatti A, Watkins F, et al. Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. *Br J Haematol* 2004; 126: 508–511.
86. Flotho C, Paulun A, Batz C, et al. AKAP12, A gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies. *Br J Haematol* 2007; 138: 644–650.
87. Akakura S and Gelman IH. Pivotal role of AKAP12 in the regulation of cellular adhesion dynamics: control of cytoskeletal architecture, cell migration, and mitogenic signaling. *J Signal Transduct* 2012; 2012: 529179.
88. Bateman NW, Jaworski E, Ao W, et al. Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. *J Proteome Res* 2015; 14: 1900–1910.
89. Muramatsu M, Akakura S, Gao L, et al. SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. *Oncotarget* 2018; 9: 33515–33527.
90. Finger EC, Castellini L, Rankin EB, et al. Hypoxic induction of AKAP12 variant 2 shifts PKA-mediated protein phosphorylation to enhance migration and metastasis of melanoma cells. *Proc Natl Acad Sci U S A* 2015; 112: 4441–4446.
91. Yoon DK, Jeong CH, Jun HO, et al. AKAP12 Induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity. *Cancer Lett* 2007; 254: 111–118.
92. Selvaraju V, Suresh SC, Thirunavukkarasu M, et al. Regulation of A-kinase-anchoring protein 12 by heat shock protein A12B to prevent ventricular dysfunction following acute myocardial infarction in diabetic rats. *J Cardiovasc Transl Res* 2017; 10: 209–220.
93. Adluri RS, Thirunavukkarasu M, Zhan L, et al. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. *J Mol Cell Cardiol* 2011; 50: 239–247.
94. You QH, Sun GY, Wang N, et al. Role of src-suppressed C kinase substrate in rat pulmonary microvascular endothelial hyperpermeability stimulated by inflammatory cytokines. *Inflamm Res* 2010; 59: 949–958.
95. Akakura S, Nochajski P, Gao L, et al. Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12. *Cell Cycle* 2010; 9: 4656–4665.
96. Qian W, Jin F, Zhao Y, et al. Downregulation of microRNA-144 inhibits proliferation and promotes the apoptosis of myelodysplastic syndrome cells through the activation of the AKAP12-dependent ERK1/2 signaling pathway. *Cell Signal* 2020; 68: 109493.
97. Liu W, Guan M, Hu T, et al. Re-expression of AKAP12 inhibits progression and metastasis potential of colorectal carcinoma in vivo and in vitro. *PLoS One* 2011; 6: e24015.
98. He P, Li K, Li SB, et al. Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer. *Int J Oncol* 2018; 52: 1305–1316.
99. Bozdogan O, Vargel I, Cavusoglu T, et al. Metastasis suppressor proteins in cutaneous squamous cell carcinoma. *Pathol Res Pract* 2016; 212: 608–615.
100. Hehnly H, Canton D, Bucko P, et al. A mitotic kinase scaffold depleted in testicular seminomas impacts spindle orientation in germ line stem cells. *Elife* 2015; 4: e09384.
101. Lin ZY, Wu CC, Chuang YH, et al. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. *Life Sci* 2013; 93: 323–328.
102. Xia W, Ni J, Zhuang J, et al. MiR-103 regulates hepatocellular carcinoma growth by targeting AKAP12. *Int J Biochem Cell Biol* 2016; 71: 1–11.
103. Choi MC, Jong HS, Kim TY, et al. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. *Oncogene* 2004; 23: 7095–7103.
104. Wang Z, Kambhampati S, Cheng Y, et al. Methylation biomarker panel performance in EsophaCap cytology samples for diagnosing Barrett’s Esophagus: a prospective validation study. *Clin Cancer Res* 2019; 25: 2127–2135.
105. Jin Z, Hamilton JP, Yang J, et al. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett’s-associated esophageal neoplastic progression. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 111–117.
106. Choi MC, Lee YU, Kim SH, et al. A-kinase anchoring protein 12 regulates the completion of cytokinesis. *Biochem Biophys Res Commun* 2008; 373: 85–89.
107. Sun Y, Ye C, Guo X, et al. Evaluation of potential regulatory function of breast cancer risk locus at 6q25.1. *Carcinogenesis* 2016; 37: 163–168.
108. Lee SW, Jung KH, Jeong CH, et al. Inhibition of endothelial cell migration through the down-regulation of MMP-9 by A-kinase anchoring protein 12. *Mol Med Rep* 2011; 4: 145–149.
109. Guo LW, Gao L, Rothschild J, et al. Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12. *J Biol Chem* 2011; 286: 38356–38366.
110. Liu Y, Gao L and Gelman IH. SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis. *BMC Cancer* 2006; 6: 105.
111. Chang J, Liu S, Li B, et al. MiR-338-3p improved lung adenocarcinoma by AKAP12 suppression. *Arch Med Sci* 2019; 17: 462–473.
112. Xue D, Lu H, Xu HY, et al. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12. *J Cell Mol Med* 2018; 22: 3223–3237.

**Author biography**

Hui Li is a professor at Central Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine and specializes in the prevention and therapy of liver fibrosis.